SCHEMBL3016502

SCHEMBL3016502

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4cccc(Br)c4)CC3)n2)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.56
HSD17B10 Q99714 2/20 0.56
USP2 O75604 1/20 0.56
RECQL P46063 1/20 0.56
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
LMNA P02545 4/20 0.46
RAB9A P51151 3/20 0.46
REV1 Q9UBZ9 1/20 0.46
HPGD P15428 2/20 0.46
AR P10275 1/20 0.46
CYP1A1 P04798 1/20 0.45
CYP1B1 Q16678 1/20 0.45
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KDM4E B2RXH2 2/20 0.44
PLAU P00749 1/20 0.44
MAPK1 P28482 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005789 0.93 MAPT (0.56) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3016289 0.90 MAPT (0.59) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3018726 0.90 MAPT (0.54) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3002608 0.89 MAPT (0.56) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3008862 0.89 MAPT (0.64) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3018756 0.88 MAPT (0.63) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3010938 0.87 MAPT (0.62) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3007674 0.87 HSD17B10 (0.58) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3016910 0.87 MAPT (0.56) MAPTHSD17B10USP2RECQLPOLB
SCHEMBL3015252 0.86 GAA (0.52) MAPTHSD17B10USP2RECQLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.